Segment and Geographic Information

Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. There are certain corporate and centralized expenses that are not allocated to the segments.

The Company’s management evaluates performance of the segments and allocates resources based on net sales and segment earnings before interest, taxes, and amortization ("Segment EBITA"). Segment EBITA represents income before income taxes, excluding interest expense, interest income, amortization of intangible assets, centralized distribution costs, certain corporate charges, and other items not allocated to the segments.

The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 27, 2018. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment.

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

Net Sales



	Three months ended				Six months ended
(in millions)	October 26, 2018		October 27, 2017		October 26, 2018		October 27, 2017
Cardiac and Vascular Group	$	2,858	$	2,773	$	5,669	$	5,419
Minimally Invasive Therapies Group	2,047		1,952		4,099		4,438
Restorative Therapies Group	1,993		1,863		3,942		3,672
Diabetes Group	583		462		1,155		911
Total	$	7,481	$	7,050	$	14,865	$	14,440

Segment EBITA



	Three months ended						Six months ended
(in millions)	October 26, 2018			October 27, 2017			October 26, 2018			October 27, 2017
Cardiac and Vascular Group	$	1,140		$	1,104		$	2,191		$	2,115
Minimally Invasive Therapies Group	792			761			1,569			1,636
Restorative Therapies Group	805			750			1,571			1,430
Diabetes Group	176			91			349			202
Segment EBITA	2,913			2,706			5,680			5,383
Interest expense	(241		)	(273		)	(483		)	(559		)
Interest income	66			100			147			192
Amortization of intangible assets	(445		)	(460		)	(891		)	(914		)
Corporate	(335		)	(339		)	(646		)	(616		)
Centralized distribution costs	(482		)	(486		)	(929		)	(928		)
Restructuring and associated costs	(77		)	(18		)	(190		)	(32		)
Acquisition-related items	(4		)	(18		)	(40		)	(71		)
Gain/(loss) on minority investments	(25		)	—			85			—
IPR&D charges	(15		)	—			(15		)	—
Certain litigation charges	—			—			(103		)	—
Exit of business	—			—			(80		)	—
Divestiture-related items	—			(67		)	—			(115		)
Gain on sale of businesses	—			697			—			697
Contribution to Medtronic Foundation	—			(80		)	—			(80		)
Hurricane Maria	—			(34		)	—			(34		)
Income Before Income Taxes	$	1,355		$	1,728		$	2,535		$	2,923

Geographic Information

Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three and six months ended October 26, 2018 and October 27, 2017 for the Company's country of domicile, countries with significant concentrations, and all other countries:



	Three months ended				Six months ended
(in millions)	October 26, 2018		October 27, 2017		October 26, 2018		October 27, 2017
Ireland	$	22	$	22	$	44	$	42

United States	4,045		3,734		7,909		7,776
Rest of world	3,414		3,294		6,912		6,622
Total other countries, excluding Ireland	7,459		7,028		14,821		14,398
Total	$	7,481	$	7,050	$	14,865	$	14,440